Takeda GI Deal History & Licensing Activity
Takeda GI is a large pharma headquartered in Japan. Over the past three years, Takeda GI has been involved in 2 licensing and acquisition transactions, with a primary focus on Peptides (4 deals).
Deals (12mo)
2
Active Trials
25
Top Modality
Peptides
Focus Area
Mega Deals
Takeda GI Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Takeda GI in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| rusfertide | Takeda | Peptides | Unknown | license | Apr 2026 |
| rusfertide | Takeda | Peptides | Unknown | license | Apr 2026 |
Takeda GI Pipeline Focus
Therapeutic areas and modalities where Takeda GI is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Takeda GI Strategic Signals
Key indicators of Takeda GI's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
See How Your Asset Matches Takeda GI's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Mega Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Peptides Benchmarks
Upfront, milestone, and royalty benchmarks for peptides deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Takeda GI Licensing & Deal Activity
Takeda GI is a large pharma company based in Japan that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Takeda GI ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Takeda GI include Mega Deals (4 deals and trials). In terms of modality, Takeda GI has shown particular interest in peptides.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Takeda GI and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Takeda GI's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.